Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755328 | 1.00 | CHRNA7 (0.54) | CHRNA7REV1KDM4EGLARCE1 | |
| Hydrochloric Acid SCHEMBL30842786 | 0.99 | CHRNA7 (0.53) | CHRNA7REV1KDM4EGLARCE1 | |
| Hydrochloric Acid SCHEMBL28460391 | 0.99 | CHRNA7 (0.53) | CHRNA7REV1KDM4EGLARCE1 | |
| SCHEMBL22997884 | 0.90 | AOC3 (0.43) | CHRNA7KDM4EMAPK1HSD17B10 | |
| SCHEMBL31268130 | 0.82 | MAOA (0.47) | CHRNA7KDM4EGLARCE1HSD17B10 | |
| SCHEMBL251439 | 0.82 | MAOA (0.47) | CHRNA7KDM4EGLARCE1HSD17B10 | |
| SCHEMBL17144907 | 0.82 | MAOA (0.47) | CHRNA7KDM4EGLARCE1HSD17B10 | |
| SCHEMBL28933503 | 0.81 | PDE4D (0.44) | KDM4EGLAMAPK1HSD17B10 | |
| SCHEMBL30019618 | 0.81 | PDE4D (0.44) | KDM4EGLAMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL4772044 | 0.80 | MAOA (0.46) | CHRNA7KDM4EGLARCE1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110054588-B | Synthetic method of 6-benzyloxy-7-methoxy-3, 4-dihydroisoquinoline | 江苏省原子医学研究所 | 2020-09-22 | — | — | CN | claimed |
| US-20250333413-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4606429-A2 | VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4590676-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4168409-B1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119907800-A | Hexahydro-2H-pyrido [2,1-a ] isoquinoline VMAT2 inhibitors and methods of use thereof | 纽罗克里生物科学有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240010647-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES, INC. | 2024-01-11 | — | — | US | disclosed |
| CN-117062815-A | VMAT2 inhibitors and methods of use | 纽罗克里生物科学有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20100222340-A1 | SUBSTITUTED PYRIDO [1,2-a] ISOQUINOLINE DERIVATIVES | BOEHRINGER MARKUS | 2010-09-02 | — | — | US | disclosed |
| EP-1551844-B1 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR SAU (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2138496-A1 | Antitumoral analogs of lamellarins | Pharma Mar, S.A.U. (ES) | 2009-12-30 | — | — | EP | disclosed |
| US-7396837-B2 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2008-07-08 | — | — | US | disclosed |
| EP-1851216-A2 | SUBSTITUTED BENZOQUINOLIZINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2006-08-03 | — | — | US | disclosed |
| WO-2006058628-A2 | SUBSTITUTED BENZOQUINOLIZINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116393-A1 | Substituted pyrido [2,1-a] isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-01 | — | — | US | disclosed |
| EP-1551844-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | Pharma Mar, S.A.U. (ES) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004014917-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR, S.A.U. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116393-A1 | Substituted pyrido [2,1-a] isoquinoline derivatives | DPP4, DPP7, DPP3 | CHRNA7 1964/4885REV1 2521/4885KDM4E 1107/4885 |
| US-20250333413-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | SLC18A2, SLC6A2, SLC18A1 | CHRNA7 650/4885REV1 3554/4885KDM4E 1751/4885 |
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PLIN3, LPAR3, LPAR2 | CHRNA7 1823/4885REV1 1015/4885KDM4E 4834/4885 |
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | SLC18A2, SLC6A2, SLC18A1 | CHRNA7 650/4885REV1 3554/4885KDM4E 1751/4885 |
| US-20100222340-A1 | SUBSTITUTED PYRIDO [1,2-a] ISOQUINOLINE DERIVATIVES | DPP4, DPP7, DPP3 | CHRNA7 1963/4885REV1 2435/4885KDM4E 1088/4885 |
| US-20240010647-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | SLC18A2, SLC6A2, SLC18A1 | CHRNA7 650/4885REV1 3554/4885KDM4E 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.